RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

PURPOSE: Sorafenib is an oral multikinase inhibitor with regulatory approval in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and refractory differentiated thyroid carcinoma (DTC). Vascular endothelial growth factor receptor (VEGFR) inhibitors like sorafenib may cause proteinur...

Descripción completa

Detalles Bibliográficos
Autores principales: Oya, Mototsugu, Kaneko, Shuichi, Imai, Tsuneo, Tsujino, Toshiaki, Sunaya, Toshiyuki, Okayama, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135823/
https://www.ncbi.nlm.nih.gov/pubmed/35445315
http://dx.doi.org/10.1007/s00280-022-04428-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135823/
https://www.ncbi.nlm.nih.gov/pubmed/35445315
http://dx.doi.org/10.1007/s00280-022-04428-0

Ejemplares similares